Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more
Lipum AB (LIPUM) - Total Assets
Latest total assets as of December 2025: Skr6.88 Million SEK
Based on the latest financial reports, Lipum AB (LIPUM) holds total assets worth Skr6.88 Million SEK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lipum AB - Total Assets Trend (2017–2025)
This chart illustrates how Lipum AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lipum AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Lipum AB's total assets of Skr6.88 Million consist of 98.6% current assets and 1.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 22.6% |
| Accounts Receivable | Skr1.49 Million | 21.7% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lipum AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipum AB's current assets represent 98.6% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 22.6% of total assets in 2025, down from 92.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 21.7% of total assets.
Lipum AB Competitors by Total Assets
Key competitors of Lipum AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lipum AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lipum AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lipum AB is currently not profitable relative to its asset base.
Lipum AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 2.10 | 0.78 |
| Quick Ratio | 0.58 | 2.10 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-4.84 Million | Skr 23.72 Million | Skr -1.41 Million |
Lipum AB - Advanced Valuation Insights
This section examines the relationship between Lipum AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.19 |
| Latest Market Cap to Assets Ratio | 1.14 |
| Asset Growth Rate (YoY) | -84.9% |
| Total Assets | Skr6.88 Million |
| Market Capitalization | $7.85 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lipum AB's assets above their book value (1.14 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Lipum AB's assets decreased by 84.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipum AB (2017–2025)
The table below shows the annual total assets of Lipum AB from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr6.88 Million | -84.87% |
| 2024-12-31 | Skr45.51 Million | +275.79% |
| 2023-12-31 | Skr12.11 Million | -64.95% |
| 2022-12-31 | Skr34.55 Million | -30.43% |
| 2021-12-31 | Skr49.66 Million | +392.27% |
| 2020-12-31 | Skr10.09 Million | -42.50% |
| 2019-12-31 | Skr17.54 Million | +91.81% |
| 2018-12-31 | Skr9.15 Million | +204.86% |
| 2017-12-31 | Skr3.00 Million | -- |